S100P and lung carcinoma: LncRNA NORAD was discovered to exploit a novel mechanism for regulating protein function.65, 66 Tan et al indicated that LncRNA NORAD was down‐regulated in lung cancers and that NORAD low expression was associated with lymph node metastasis and poor prognosis.67 Mechanistically, NORAD exploited its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing the associated pro‐metastatic signalling network of S100P.